Meyka Pro banner
Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) Stock Competitors & Peer Comparison

See TNDM's competitors and their performance on the NASDAQ and across the wider stock market.

TNDMNASDAQ
HealthcareMedical - Devices
$23.13
$0.31(1.32%)
U.S. Market opens in 3h 55m

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for TNDM and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
TNDM$22.38+19.11%1.5B-20.35-$1.10N/A
ABT$107.81-0.14%186.5B20.69$5.21+2.31%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
SYK$339.03+0.47%130B25.32$13.39+1.03%
MDT$87.16+1.44%111.6B15.76$5.53+3.29%
BSX$49.31+0.02%73.3B15.91$3.10N/A
EW$89.72+0.45%51.7B33.23$2.70N/A
DXCM$84.75+2.08%32B36.37$2.33N/A
RMD$211.94-5.06%30.7B19.68$10.77+1.15%
PHG$26.73+1.52%26.1B15.28$1.75+3.70%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Abbott Laboratories (NYSE: ABT)

TNDM vs ABT Comparison August 2026

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TNDM stands at 1.5B. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, TNDM is priced at $22.38 on the NASDAQ, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TNDM currently has a P/E ratio of -20.35, whereas ABT's P/E ratio is 20.69. In terms of profitability, TNDM's ROE is -0.46%, compared to ABT's ROE of +0.11%. Regarding short-term risk, TNDM is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for TNDM.Check ABT's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions